Cytomegalovirus infection secondary prevention

Cytomegalovirus infection Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cytomegalovirus infection from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cytomegalovirus infection secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cytomegalovirus infection secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cytomegalovirus infection secondary prevention
CDC on Cytomegalovirus infection secondary prevention
Cytomegalovirus infection secondary prevention in the news
Blogs on Cytomegalovirus infection secondary prevention
Directions to Hospitals Treating Cytomegalovirus infection
Risk calculators and risk factors for Cytomegalovirus infection secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Kuchkuntla, M.B.B.S[2]

Secondary Prevention

• Preemptive treatment with antiviral agents in asymptomatic patients with positive blood PCR for CMV DNA.